NCT02277613终止2 期
A Phase 2 Prospective, Randomized, Double-blind, Sham-controlled, Parallel-group, Multi-center Trial of AMI MultiStem® Therapy in Subjects With Non-ST Elevation Acute Myocardial Infarction
适应症
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 发起方
- Healios K.K.
- 入组人数
- 34
- 试验地点
- 11
- 主要终点
- Incidence and severity of adverse events
研究概览
简要总结
This is a double-blind, sham-controlled clinical study to evaluate the safety and feasibility of AMI MultiStem therapy in subjects who have had a heart attack (Non-ST elevation MI).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 85 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subjects of either gender, 18-85 years of age, inclusive
- •Diagnosis of non-ST elevation myocardial infarction (NSTEMI)
- •Left Ventricular Ejection Fraction (LVEF) between ≥ 25 and ≤ 45%
排除标准
- •Previous Coronary Artery Bypass Graft (CABG)
- •Previous autologous, allogeneic bone marrow or peripheral stem cell transplant
- •Previous solid organ transplant
- •Anticipated need for additional planned coronary revascularization procedure(s)
- •Hemodynamic instability
- •Mechanical complications of the index acute myocardial infarction
结局指标
主要结局
Incidence and severity of adverse events
时间窗: 30 days
To compare the difference in the incidence and severity of adverse events between AMI MultiStem therapy treated subjects and Sham treated subjects
To assess the effects of AMI MultiStem therapy on cardiac function
时间窗: Day 120
To compare the changes in cardiac function assessed by cardiac MRI between AMI MultiStem therapy treated subjects and Sham treated subjects
次要结局
- To assess the incidence of Major Adverse Cardiovascular Events (MACE)(Day 365)
- Incidence and severity of adverse events(Day 365)
- To assess the effects of AMI MultiStem therapy on cardiac function(Day 365)
研究者
研究点 (11)
Loading locations...
相似试验
进行中（未招募）
2 期
Efficacy and Safety of AC102 Compared to Steroids in Adults With Idiopathic Sudden Sensorineural Hearing Loss (ISSNHL)Hearing Loss, SensorineuralNCT05776459AudioCure Pharma GmbH210
已完成
2 期
A Randomized Phase 2 Study of AT-101 in Combination With Docetaxel in Relapsed/Refractory Non-Small Cell Lung CancerNon-small Cell Lung CancerNCT00544960Ascenta Therapeutics106
已完成
2 期
Study to Assess the Efficacy and Safety of Atuliflapon in Moderate-to-Severe Uncontrolled AsthmaAsthmaNCT05251259AstraZeneca670
招募中
2 期
MDMA-Assisted Therapy for Veterans With Moderate to Severe Post Traumatic Stress DisorderPost Traumatic Stress DisorderNCT05790239Stephen Robert Marder40
已完成
2 期
ATI-501 Oral Suspension Compared to Placebo in Subjects With Alopecia Areata, Alopecia Universalis or Alopecia TotalisAlopeciaNCT03594227Aclaris Therapeutics, Inc.87